217.492.9100

Coronary Trials

  • Victorion 2 Prevent

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

  • Prolocor

This is a Prospective, Observational Multicenter Non-Interventional Cohort Study. The primary objective is to determine whether platelet expression of FcγRIIa is associated with risk of myocardial infarction (MI), stroke and death. Secondary objectives include: 1) Develop a score that combines clinical characteristics plus platelet expression of FcγRIIa to determine the risk of MI, stroke, and death; and 2) Determine whether platelet expression of FcγRIIa is associated with risk of major bleeding. The primary endpoint is the composite of death, MI and stroke. A secondary endpoint is the incidence of clinically significant bleeding according to the Bleeding Academic Research Consortium (BARC) scale type 2-5. Approximately 800 male and female subjects with confirmed MI [ST-segment elevation MI (STEMI) or non-ST-segment elevation MI (NSTEMI)] will be enrolled before hospital discharge for the index event. Approximately 10 sites in the United States will participate in this study. It is anticipated that it will take approximately 12 months to enroll approximately 800 subjects. The study and subject follow-up will continue until 1) at least 80 ischemic events (MI, stroke, and death) have occurred, and 2) the last subject enrolled has completed 18 months of follow-up.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

  • Phillip Morris

A 12-month, 3-group, preference, multi-center study to demonstrate the effects of switching from cigarettes to Tobacco Heating System (THS) on systemic endothelial function in subjects with established atherosclerotic disease.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

 

Peripheral Trials

  • CREST II

Carotid revascularization and medical management for asymptomatic carotid stenosis trial

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02089217

  •  TARGET BP

A randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation – no alcohol infusion). Subjects will be randomized in a 1:1 fashion to treatment versus sham control via central randomization.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02910414

  • Elegance

      The ELEGANCE Registry’s objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.

      If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

      https://clinicaltrials.gov/ct2/show/NCT04674969?term=04674969&draw=2&rank=1

      •  C Guardians

          The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS).

          If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

          • Radiance

              RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects with uncontrolled hypertension despite the prescription of antihypertensive medications.

              If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

              • Reduced 1

                  The TIVUS II is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System consisting of three (3) concurrent cohorts:  Severe Resistance HTN, Moderate Resistance HTN, and Failed RF Therapy.

                  If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                  Structural Heart Trials

                    • AMPLATZER™ PFO Occluder Post-Approval Study

                    AMPLATZER™ PFO Occluder Post Approval Clinical Study is a single arm, multi-center study to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder, in a post approval setting, in patients with a PFO who have had a cryptogenic stroke confirmed by a study neurologist.

                    If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                    https://clinicaltrials.gov/ct2/show/NCT03309332

                    •  ACURATE IDE

                    A prospective, multicenter trial designed to evaluate the safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for TAVR in subjects who have sever native aortic stenosis and are indicated for TAVR.

                    If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                    Website pending…

                    • SUMMIT

                    Prospective, controlled, multicenter clinical investigation of the Tendyne Mitral Valve System for the treatment of eligible subjects with symptomatic, severe, mitral regurgitation.

                    If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                    Website pending…

                    •  Empower

                    The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the CARILLON Mitral Contour System in treating heart failure with at least mild functional regurgitation.

                      If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                      • Repair MR

                      The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.

                        If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                        EP Trials

                          • SOLVE CRT

                          A prospective, multi-center, randomized, controlled, double blinded, pivotal trial to study the safety and efficacy of the WiSE-LV System for Cardiac Re-synchronization Therapy. The WiSE-LV System is an implantable cardiac pacing system capable of delivering pacing energy to the left ventricle of the heart without using a pacing lead.

                          If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                          https://clinicaltrials.gov/ct2/show/study/NCT02922036

                          •   INTERRUPT AF

                          A prospective, non-randomized, multicenter (global), post approval clinical study (PAS) to evaluate open irrigated ablation catheters with high resolution mapping to treat paroxysmal atrial fibrillation.

                          If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                          https://clinicaltrials.gov/ct2/show/NCT03729830

                          •  HEAL

                          The objective of this study is to gather information on participants returning at time of CIED change-out or revision who underwent a device implantation with either a CanGaroo® envelope, Tyrx™ envelope, or no envelope.

                          If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                          https://clinicaltrials.gov/ct2/show/NCT04645173?cond=cangaroo&draw=2&rank=1

                          •  Real AF

                          The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.

                          If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                              •  Advantage AF

                              The objective of the ADVANTAGE AF Study is to establish the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System (FARAPULSE PFA System) for treatment of drug resistant, symptomatic persistent atrial fibrillation (PersAF).

                                  If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                                  Heart Failure Trials

                                  • Rebalance HF

                                  The objective of this clinical evaluation is to assess the safety and initial effectiveness of catheter-based unilateral ablation of the right greater splanchnic nerve (GSN) in subjects having heart failure with preserved ejection fraction (HFpEF).

                                  If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                                  https://clinicaltrials.gov/ct2/show/NCT04592445?cond=rebalance+hf&draw=2&rank=1

                                  • Allay HF

                                  Study to evaluate the safety and efficacy of the Alleviant System for no-implant interatrial shunt creation in patients with chronic heart failure.

                                  If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                                  https://clinicaltrials.gov/ct2/show/NCT04592445?cond=rebalance+hf&draw=2&rank=1

                                      Registry 

                                        • Care HF

                                        Cardiovascular and renal treatment in heart failure patients with Hyperkalemia or at high risk of hyperkalemia

                                        If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

                                        More Coming soon…..